E-viri
Recenzirano
-
Lagalla, Giovanni; Millevolte, Marzia; Capecci, Marianna; Provinciali, Leandro; Ceravolo, Maria Gabriella
Movement disorders, 20/May , Letnik: 21, Številka: 5Journal Article
To investigate the safety and efficacy of botulinum toxin type A (BoNTX) treatment to reduce sialorrhea in Parkinson's disease (PD), a double‐blind, randomized, placebo‐controlled study enrolled 32 PD patients complaining of excessive drooling. Patients received either 50 U Botox in each parotid gland or placebo without using ultrasound guidance. Subjects treated with BoNTX experienced a reduction in both drooling frequency and familial and social disability (Time × Group effect: P < 0.01), as well as in saliva production (Time × Group effect: P < 0.0001). No adverse events were recorded. BoNTX injections are safe and effective treatment for the management of PD‐related drooling. © 2006 Movement Disorder Society
